 Atea Pharmaceuticals Inc NASDAQ: AVIR has announced positive interim results from a Phase 2 study evaluating AT-527 in hospitalized patients with mild-to-moderate COVID-19. Roche Holding AG OTC: RHHBY and Atea jointly develop AT-527, an oral direct-acting antiviral agent derived from Ateas purine nucleotide prodrug platform. 